Healthcare -
Biotechnology - NASDAQ - AU
$ 1.6
-0.621 %
$ 233 M
Market Cap
-7.62
P/E
1. INTRINSIC VALUE
Balance Sheet
Immutep Limited
| Current Assets | 191 M |
| Cash & Short-Term Investments | 182 M |
| Receivables | 5.24 K |
| Other Current Assets | 9.47 M |
| Non-Current Assets | 10.2 M |
| Long-Term Investments | 0 |
| PP&E | 680 K |
| Other Non-Current Assets | 9.55 M |
| Current Liabilities | 10.5 M |
| Accounts Payable | 3.79 M |
| Short-Term Debt | 234 K |
| Other Current Liabilities | 6.46 M |
| Non-Current Liabilities | 1.57 M |
| Long-Term Debt | 1.36 M |
| Other Non-Current Liabilities | 211 K |
EFFICIENCY
Earnings Waterfall
Immutep Limited
| Revenue | 3.84 M |
| Cost Of Revenue | 41.5 M |
| Gross Profit | -37.7 M |
| Operating Expenses | 50.4 M |
| Operating Income | -88.1 M |
| Other Expenses | -45.4 M |
| Net Income | -42.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immutep Limited
| Net Income | -42.7 M |
| Depreciation & Amortization | 2.26 M |
| Capital Expenditures | -932 K |
| Stock-Based Compensation | 1.8 M |
| Change in Working Capital | 3.46 M |
| Others | 3.24 M |
| Free Cash Flow | -35.8 M |
Wall Street Analysts Price Targets
Immutep Limited
Wall Street analysts predict an average 1-year price target for IMMP of $7.2 , with forecasts ranging from
a
low of
$6 to a high of $10 .
IMMP Lowest Price Target
Wall Street Target
6 USD
275.00%
IMMP Average Price Target
Wall Street Target
7.2 USD
350.00%
IMMP Highest Price Target
Wall Street Target
10 USD
525.00%
4. DIVIDEND
ANALYSIS
IMMP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Immutep Limited
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study's prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma (STS).
globenewswire.com
- 3 weeks ago
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
Immutep Limited IMMP on Thursday announced additional data from the investigator-initiated INSIGHT-003 trial evaluating a triple combination therapy in front-line non-small cell lung cancer patients consisting of efti administered in conjunction with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy (carboplatin and pemetrexed).
benzinga.com
- 1 month ago
Immutep Limited: Surging On Positive Head And Neck Data
Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval.
seekingalpha.com
- 1 month ago
Immutep to Participate in Upcoming Investor Conferences
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:
globenewswire.com
- 2 months ago
Immutep Quarterly Activities Report Q2 FY25
Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controls Promising new results in first line head & neck cancer with PD-L1 CPS
globenewswire.com
- 4 months ago
Immutep Limited: Continuing To Make The Case For Eftilagimod
Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns.
seekingalpha.com
- 4 months ago
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. Through the first three of five single ascending dose cohorts in healthy participants, there have been no treatment related adverse events.
globenewswire.com
- 6 months ago
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression.
globenewswire.com
- 6 months ago
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031.
seekingalpha.com
- 7 months ago
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients.
benzinga.com
- 7 months ago
Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controls Safety continues to be favourable with no new safety signals INSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase III trial SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients. Prof. Dr. Salah-Eddin Al-Batran of the Frankfurt Institute of Clinical Cancer Research (IKF) and project lead stated, “The strength of these mature survival results coupled with a favourable safety profile in first-line treatment of patients with non-squamous NSCLC, the vast majority of whom have negative or low PD-L1 expression, is very encouraging.
globenewswire.com
- 7 months ago
Immutep Quarterly Activities Report Q1 FY25
SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25).
globenewswire.com
- 7 months ago
8. Profile
Summary
Immutep Limited IMMP
COUNTRY
AU
INDUSTRY
Biotechnology
MARKET CAP
$ 233 M
Dividend Yield
0.00%
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Contact
Australia Square, Sydney, NSW, 2000
https://www.immutep.com
IPO
Date
April 19, 2012
Employees
41
Officers
Mr. Christian Mueller BBA, MSc.
Chief Development Officer
Ms. Deanne Miller LLB
Chief Operating Officer, General Counsel & Joint Company Secretary
Dr. Frederic Triebel M.D., Ph.D.
Chief Scientific Officer & Executive Director
Mr. Stephan Winckels M.D., Ph.D.
Acting Chief Medical Officer
Ms. Indira Naidu
Joint Company Secretary
Mr. Marc Voigt
Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director